These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 19461031)

  • 21. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Szarek M; Sillesen H; Rudolph AE; Callahan A; Hennerici M; Simunovic L; Zivin JA; Welch KM;
    Stroke; 2007 Dec; 38(12):3198-204. PubMed ID: 17962589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of torcetrapib on the progression of coronary atherosclerosis.
    Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
    N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol.
    Wang KY; Ting CT
    Jpn Heart J; 2001 Nov; 42(6):725-38. PubMed ID: 11933922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients.
    Chan LW; Luo XP; Ni HC; Shi HM; Liu L; Wen ZC; Gu XY; Qiao J; Li J
    Braz J Med Biol Res; 2015 Feb; 48(2):167-73. PubMed ID: 25466164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
    Schrott HG; Knapp H; Davila M; Shurzinske L; Black D
    Am Heart J; 2000 Aug; 140(2):249-52. PubMed ID: 10925339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
    J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of atorvastatin of the treatment of hypercholesterolemia after renal transplantation.
    Alvarez ML; Errasti P; Gómez G; Lavilla FJ; García N; Ballester B; García I; Purroy A
    Transplant Proc; 1999 Sep; 31(6):2328-9. PubMed ID: 10500602
    [No Abstract]   [Full Text] [Related]  

  • 34. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.
    Velussi M; Cernigoi AM; Tortul C; Merni M
    Diabetes Nutr Metab; 1999 Dec; 12(6):407-12. PubMed ID: 10782562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [CME-Lab 2/Solution. Hypercholesteremia and therapy control].
    von Eckardstein A
    Praxis (Bern 1994); 2007 Apr; 96(17):701-2. PubMed ID: 17491201
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
    Kosmidou MS; Hatzitolios AI; Adamidou A; Giannopoulos S; Raikos N; Parharidis G; Milionis HJ
    Am J Hypertens; 2008 Mar; 21(3):303-9. PubMed ID: 18202666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.